Advanced search
Publication Cover
Hematology Volume 28, 2023 - Issue 1
Submit an article Journal homepage
1,508
Views
0
CrossRef citations to date
0
Altmetric
Research Article

A cross-sectional survey of symptoms and daily living among patients with polycythemia vera and their treating physicians in Japan

Yoko Edahiroa Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan;b Laboratory for the Development of Therapeutics Against MPN, Juntendo University Graduate School of Medicine, Tokyo, Japan;c Department of Advanced Hematology, Juntendo University Graduate School of Medicine, Tokyo, JapanCorrespondence[email protected]
View further author information
,
Keita Kiritod Department of Hematology and Oncology, University of Yamanashi, Yamanashi, JapanView further author information
,
Akihiko Gotohe Department of Hematology, Tokyo Medical University, Tokyo, JapanView further author information
,
Katsuto Takenakaf Department of Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, JapanView further author information
,
Yuka Sugimotog Department of Hematology and Oncology, Mie University Graduate School of Medicine, Mie, JapanView further author information
,
Norio Komatsua Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan;b Laboratory for the Development of Therapeutics Against MPN, Juntendo University Graduate School of Medicine, Tokyo, Japan;c Department of Advanced Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan;h PharmaEssentia Japan K.K., Tokyo, JapanView further author information
&
Kazuya Shimodai Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, JapanView further author information
 show all
Article: 2227817 | Received 14 Mar 2023, Accepted 16 Jun 2023, Published online: 11 Jul 2023

References

  • Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia. 2021;35:3339–3351. doi:10.1038/s41375-021-01401-3
  • Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109:68–76. doi:10.1002/cncr.22365
  • Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30:4098–4103. doi:10.1200/JCO.2012.42.3863
  • Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN landmark survey. BMC Cancer. 2016;16:167. doi:10.1186/s12885-016-2208-2
  • Mesa R, Boccia RV, Grunwald MR, et al. Patient-reported outcomes data from REVEAL at the time of enrollment (baseline): a prospective observational study of patients with polycythemia vera in the United States. Clin Lymphoma Myeloma Leuk. 2018;18:590–596. doi:10.1016/j.clml.2018.05.020
  • Harrison CN, Koschmieder S, Foltz L, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN landmark survey. Ann Hematol. 2017;96:1653–1665. doi:10.1007/s00277-017-3082-y
  • Yu J, Parasuraman S, Paranagama D, et al. Impact of myeloproliferative neoplasms on patients’ employment status and work productivity in the United States: results from the living with MPNs survey. BMC Cancer. 2018;18:420. doi:10.1186/s12885-018-4322-9
  • Byun JM, Bang SM, Choi EJ, et al. How myeloproliferative neoplasms patients’ experience and expectations differ from physicians’: the international MPN landmark survey. Korean J Intern Med. 2022;37:444–454. doi:10.3904/kjim.2021.475
  • Brochmann N, Flachs EM, Christensen AI, et al. Health-related quality of life in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark. Cancers (Basel). 2020;12:3565. doi:10.3390/cancers12123565
  • Mesa RA, Miller CB, Thyne M, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: findings from the MPN landmark survey. Cancer. 2017;123:449–458. doi:10.1002/cncr.30325
  • Scherber R, Dueck AC, Johansson P, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118:401–408. doi:10.1182/blood-2011-01-328955
  • Shimoda K, Takahashi N, Kirito K, et al. JSH Practical guidelines for hematological malignancies, 2018: I. Leukemia-4. chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN). Int J Hematol. 2020;112:268–291. doi:10.1007/s12185-020-02964-0
  • Passamonti F. New and old prognostic factors in polycythemia vera. Curr Hematol Malig Rep. 2009;4:19–24. doi:10.1007/s11899-009-0003-8
  • Scherber RM, Kosiorek HE, Senyak Z, et al. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer. 2016;122:477–485. doi:10.1002/cncr.29753
  • Siegel FP, Tauscher J, Petrides PE. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. Am J Hematol. 2013;88:665–669. doi:10.1002/ajh.23474
  • Duek A, Berla M, Ellis MH. Recent advances in the treatment of polycythemia vera. Leuk Lymphoma. 2022;63:1801–1809. doi:10.1080/10428194.2022.2057491

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.